Biostage is a biotechnology company developing bioengineered organ implants based on the Company's Cellframe™ technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants.
Cellspan implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients.
Based on its pre-clinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.
June 20, 2021
RegMed Investors’ (RMi) closing bell: could have been worse
June 18, 2021
RegMed Investors’ (RMi) pre-open: the witch is on the stick
June 17, 2021
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector rallied after a two (2) session flogging
June 17, 2021
RegMed Investors’ (RMi) pre-open: uncertainty as liquidity of pricing reflects conflicted value
June 16, 2021
RegMed Investors’ (RMi) closing bell: as expected, gravity induced by the Fed was a sector force
June 16, 2021
RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results
June 16, 2021
Q2/21 Earnings - (LPS - loss-per-share) Results
June 16, 2021
RegMed Investors’ (RMi) pre-open: Waiting for Powell
June 15, 2021
RegMed Investors’ (RMi) closing bell: the sector stampeded to the downside, told you so!
June 15, 2021
RegMed Investors’ (RMi) pre-open: are you ready …
35 companies, 1 interpreter!
Insight, foresight and recommendation
Biostage (BSTG) - The implementation of this reverse stock split will continue CEO McGorry’s “abuse and destruction of the shareholder value due to his mismanagement, misdirection and misdeeds”. It’s all about salary and “bennies” continuance, violations of fiduciary omittance and having condoned and ignored employee – male and female harassment.” And if that isn’t enough … Is Biostage (BSTG) a Ponzi or Pyramid scheme or a combination of both …? A $300 K down payment and $4 M buys a shell from which $30 M was wasted and a $47 M deficit created …
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2021 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.